Postdoctoral Research Scholar in Computational Oncology - Jake Lee Lab

About the role

The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert care to patients of all ages. Informed by basic research done at our Sloan Kettering Institute, scientists across MSK collaborate to conduct innovative translational and clinical research that is driving a revolution in our understanding of cancer as a disease and improving the ability to prevent, diagnose, and treat it. MSK is dedicated to training the next generation of scientists and clinicians, who go on to pursue our mission at MSK and around the globe. Join the Lee Lab: Cancer Genome History & Therapeutics at MSK. We study the mutational processes and genomic rearrangements that drive cancer evolution and therapy resistance using high-throughput sequencing as the main toolkit. We are seeking a highly motivated postdoctoral fellow with strong expertise in computational biology to lead projects at the interface of cancer biology, single-cell genomics, and clinical oncology. Project focus: You will analyze single-cell whole-genome sequencing data jointly with other multi-omic datasets from i) genetically engineered mouse models, ii) PDX/PDO systems, and iii) clinical tumor samples to define evolutionary trajectories of extrachromosomal circular DNA-mediated oncogene amplification. This position offers a unique opportunity to work in a highly collaborative and translational environment, closely partnering with experimental scientists and clinician investigators. The position is supported by a grant from the Burroughs Wellcome Fund. https://www.mskcc.org/profile/jake-june-koo-lee The Lee Lab is a newly established computational research group within MSK Computational Oncology focused on the mutational mechanisms and rearrangement processes that drive cancer genome evolution. We seek to uncover how and why cancer genomes acquire their complex architectures and how they continue to evolve in patients undergoing treatment. Ultimately, our goal is to identify strategies to intercept this maladaptive evolution and restore physiology. Our most recent story here: https://www.biorxiv.org/content/10.64898/2026.02.12.705658v1 Our work leverages cutting-edge sequencing technologies, including single-cell whole-genome sequencing, long-read sequencing, and multi-omic approaches. Beyond applying state-of-the-art methods, we actively adapt and extend them to address fundamental questions in cancer biology. Many of our projects are in collaboration with experimental investigators. We are committed to building a collaborative, supportive, and intellectually vibrant lab environment.